


# Technical Update

## European Union Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation

7<sup>th</sup> African Medicines Regulator's Conference  
AMDF Technical Committee Meeting

Willy Urassa  
Independent Consultant


EU Directive  EU Regulation

EU Directive 90/385/EEC on active implantable medical devices,  
Directive 93/42/EEC on medical devices (1990s)



**EU Regulation on medical devices (2017)**

EU Directive 98/79/EC on in vitro diagnostic medical devices (1990s)



**EU Regulation on in vitro diagnostic medical  
devices (2017)**

# Main Improvements-1

- Stricter pre-market assessment of high-risk devices with the involvement of a pool of experts at EU level.
- Reinforcement of the criteria for designation and of the oversight of notified bodies in charge of certifying medical devices.
- Introduction of a new risk classification system for in-vitro diagnostic medical devices based on international guidance.

# Main Improvements-2

- Reinforcement of the **rules on clinical investigation**,
- Improved **transparency** through the establishment of a **comprehensive EU database** on medical devices and of a device traceability system allowing to trace the device from its manufacturer through the supply chain to the final user.
- **Improved coordination** between Member States in the fields of **vigilance and market surveillance**.
- **Role and responsibilities of economic operators**.  
Certain new obligations for authorised representatives.


# Main Improvements-3

- **Four out of five** *in vitro* diagnostic medical devices are checked by a Notified Body before they are placed on the market
- Manufacturers will need to **generate and provide more in-depth clinical data** to prove safety and performance claims including tighter equivalency standards.
- **Manufacturer's obligations** in relation to operating **effective post-market surveillance** of their medical devices are more prescriptive including the need to **continuously update risk analysis and clinical documents**.
- **Reporting obligations for high risk devices** including the compilation of Periodic Safety Update Reports (PSURs).
- **Unique Device Identification (UDI) will be implemented** to help track devices throughout the economic operator supply chain and will be required on all labels.

# UDI

## Unique Device Identifier UDI

Machine Readable



Human Readable

(01)00827002005112(17)000004(10)1234(21)8234

(01)

UDI-DI

Device Identifier


(17)  
Expiration  
date

(10)  
Lot  
Number

(21)  
Serial  
Number

UDI-PI

Product Identifier



# Main Improvements-4

- At least **one person** in the organization be formally assigned responsibility for ensuring the **regulatory compliance** of the enterprise
- The **extension of the scope of the medical device regulations** to products without an intended medical purpose but which are analogous to devices with a medical purpose.
  - Products typically intended for cosmetic purposes.
  - Colored non-corrective contact lenses.

# Proposed transition period



## Transition Timelines from the Directives to the Regulations Medical Devices and *in vitro* Diagnostic Medical Devices





# Impact of new the EU MD regulations

- **Heightened device safety and effectiveness** and will support transparency throughout the medical device market
- Utilization of a **Unique Device Identifier (UDI)** system publicly available and easily accessible will be critical to supporting physician and patient attitudes toward various medical devices
- The overall **number of Notified Bodies is expected to decline** leading to bottlenecks and commercialization delays
- Manufacturers: **increased costs, commercialization delays, and device removals**
- **Smaller companies** will likely be **pushed out of the market**
  - Unable to comply with the MDR by the date of application,
  - Lack of resources, time constraints, or both.
  - Companies will likely have to make difficult strategic decisions to **prioritize certain products** (generate sufficient sales to cover the costs of compliance)

# Regulators Considerations

- **Prepare contingency plans** in case of
  - Reduced or delayed supply
  - Withdrawal of products
  - Critical products/all similar products
  - Products replaced
  - Inferior goods
  - IVD mark removed may lead may change to Research Use Only (RUO) status
  - ? What is going to happen the **rest of the world version products (Non-CE Marked products)**